Somatic OCD and the Exhausting Focus on Bodily Functions

Share this post:

LinkedIn
Facebook
X
Reddit
WhatsApp
Print

Somatic OCD, often called sensorimotor OCD, is a pattern in which your attention gets stuck on automatic bodily processes or physical sensations such as breathing, blinking, swallowing, heartbeat, eye contact, or muscle tension. The obsession usually is not that the body function itself is dangerous. The fear is that you will keep noticing it, keep checking it and never get back to a normal automatic state.

This form of OCD can feel confusing because the trigger is inside your own body. You cannot step away from breathing, blinking, swallowing, or the sensation of your heartbeat. Once fear locks onto one of these processes, many people start scanning for it over and over, trying to stop noticing it, or trying to prove they can still control it. Those efforts tend to make the fixation stronger. Clinical writing on sensorimotor obsessions describes selective attention as the common starting point and notes that attempts to distract yourself often increase anxiety and keep the focus in place.

Like other forms of OCD, somatic OCD follows the same broad cycle. An intrusive focus appears, distress rises, then compulsive behavior or mental ritual follows. In this subtype, the rituals may be subtle. You may check your breathing pattern, test your swallow, count blinks, monitor eye contact, use devices to check pulse, avoid quiet spaces, or keep trying to “fix” the sensation in your mind. OCD is defined by intrusive unwanted obsessions and repetitive compulsions, and those compulsions can be mental acts as well as visible behaviors.

The panic of feeling trapped in your own body

The core fear in somatic OCD is often the fear of being stuck. You may worry that your breathing will never feel automatic again, that you will never stop noticing your blink rate, or that swallowing will never return to the background. Clinical descriptions of sensorimotor obsessions note that fears often center on the concern that automatic bodily processes will fail to return to their previous unconscious state, along with the fear that the obsession itself will never end.

That fear can produce real panic. If you become aware of your breath and then start asking yourself if you are breathing correctly, the body can suddenly feel unfamiliar. The same can happen with blinking, swallowing, heartbeat, or even where to place your eyes during conversation. The process becomes exhausting because every attempt to check for improvement becomes another round of attention on the same sensation. The mind starts treating the body process like a problem that needs constant supervision.

Research on OCD has found that overactive monitoring can extend to internal bodily signals. In one study using heartbeat detection, people with OCD showed stronger monitoring of internal body cues than control groups. That finding fits the lived experience of somatic OCD, where normal internal sensations can start feeling unusually loud, sticky and hard to ignore.

This can affect concentration, sleep and social life. Clinical material on sensorimotor obsessions notes that people often report impaired concentration at work, during social situations, or while trying to fall asleep. When your attention keeps snapping back to breathing or blinking, even simple tasks can feel draining.

Fixations on swallowing breathing and eye contact

Somatic OCD can attach to many different bodily functions. The most commonly described examples include breathing, blinking, swallowing, salivation, heartbeat, eye contact and awareness of specific body parts or subtle visual experiences.

Breathing fixations often involve repeated checking of depth, pace, rhythm, chest movement, or the feeling of air in and out of the nose and throat. You may fear that once you notice your breath, you will stay conscious of it all day. Some people keep testing if breathing still feels automatic. Others keep trying to force a perfect breathing pattern. Those checks become part of the OCD cycle.

Swallowing fixations can center on how often you swallow, how saliva feels, how food moves in your throat, or whether swallowing seems “off.” Clinical treatment material on sensory OCD lists common neutralizing behaviors such as avoiding certain foods, re chewing food, eating only at home, or eating differently around other people. These behaviors may feel protective for a moment, but they keep attention tied to the symptom.

Blinking fixations may involve counting blinks, trying to blink evenly, checking one eye more than the other, or monitoring whether blinking feels natural. Since blinking is automatic and frequent, this can create a constant loop. The more you look for the sensation, the more present it feels.

Eye contact fixations can be especially hard in conversation. Clinical descriptions note that this form may involve awareness of eye contact itself or uncertainty about which eye to look at. The result can be repeated redoing, avoidance, self consciousness and a strong feeling that a basic social act has become unnatural.

Other people focus on heartbeat, stomach sensations, muscle tension, speech, hunger pain, or the feeling of a body part while reading or walking. The exact trigger can vary a lot. The pattern that keeps it going is usually the same. You notice the sensation, become alarmed by how strongly you are noticing it, then start using rituals, safety behaviors, or constant checking to get rid of it. Clinical material on sensory OCD states that these attempts to get rid of sensations are what maintain the symptoms.

Techniques to shift attention outward

Treatment usually starts with a basic but important lesson. Selective attention to a bodily process is not dangerous by itself. Clinical guidance on sensorimotor obsessions explains that the first phase of treatment often teaches people that noticing a previously automatic sensation does not create harm and that the awareness usually shifts as anxiety comes down.

From there, the work often focuses on reducing the rituals that keep the attention glued in place. These rituals can include checking, mental reviewing, bodily testing, pulse checking, mirror checking, redoing eye contact, avoiding food, avoiding silence, or scanning for the sensation before it appears. Treatment material on sensory OCD groups these responses under rituals, compulsions, avoidance, safety behaviors and reassurance seeking, all of which maintain the fixation.

A useful outward attention skill is gentle return. You notice the bodily sensation, name the spike of attention and return to the task in front of you without trying to force the sensation away. For some people that task may be reading a page, listening to another person, walking, cooking, or finishing a work step. The key is that the return is calm and repeated. Clinical writing on sensorimotor obsessions recommends a relaxed and accepting posture toward the sensation rather than a fight to suppress it.

Exposure and response prevention is also central here. Federal guidance describes ERP as a form of CBT that gradually exposes people to obsession triggers in a safe setting while preventing the usual compulsive response. In somatic OCD, that can mean allowing awareness of breathing, blinking, swallowing, or heartbeat to be present while you stop doing the checking and safety behavior that usually follows.

This works best in gradual steps. If breathing is your main trigger, the early work may involve briefly allowing awareness of your breath without trying to correct it. If swallowing is the trigger, the work may involve eating with less ritual and less checking. If eye contact is the trigger, it may involve staying in conversation without redoing where you look. The point is repeated practice in letting the sensation exist without turning it into a full alarm event. Clinical treatment material stresses that identifying each person’s neutralizing behaviors is a major part of recovery.

Many people also need to stop measuring progress every few minutes. Progress usually shows up as less panic, less ritual behavior, less avoidance and a quicker return to daily activity. The sensation may still appear. What changes is the amount of fear and ritual that attaches to it. Since OCD compulsions bring only temporary relief, stopping the repeated relief-seeking cycle is what gives the brain room to settle.

If symptoms are taking up large parts of your day, disrupting sleep, or limiting work and relationships, formal treatment can help. OCD often becomes severe when it is hidden for too long. Federal guidance notes that people with OCD can spend more than an hour a day on obsessions and compulsions and may avoid situations that trigger symptoms.

Conclusion

Questions about the mind body connection remain active in psychiatric research, and we at Rose Hill Life Sciences are a psychedelic research organization specializing in the production and research of Psilocybe cubensis, operating at the intersection of science and therapeutic integration, and are based in Massachusetts.




Disclaimer: The information in this article is for educational and informational purposes only and does not constitute medical advice.

You May Also Like

Adam Goodman

Advisor

Adam is a seasoned entrepreneur with a wealth of experience in spearheading real estate development and management endeavors. His focus primarily lies in land development, where he orchestrates the intricate tapestry of planning and zoning entitlements, while meticulously overseeing all facets of engineering and architectural design, leasing, construction, and financing.

With a national reach spanning 23 states and encompassing over 250 properties, totaling more than 6 million square feet, Adam’s proficiency in navigating the complexities of the industry is evident.

Beyond real estate, Adam’s endeavors extend into the realm of alternative investments, boasting successful ventures in healthcare, professional sports franchises, financial services, diverse agricultural platforms, and the stewardship of local restaurants.

 

Rotem Petranker, PhD, Psychology

Psychedelic Researcher

Rotem Petranker is a psychedelics researcher with a particular emphasis on microdosing, therapy, research methods and research ethics. He earned his BSc from the University of Toronto, his Master’s degree from York University, and his PhD from McMaster University.

As part of my research, I have gained extensive expertise in navigating the regulatory landscapes of Health Canada and the FDA and a strong background in designing rigorous clinical trial research methodologies. 

I founded the Canadian Centre for Psychedelic Science in 2018, established the Psychedelic Science Research Program at the University of Toronto in 2019, and, more recently, ran the largest clinical trial to date on the effectiveness of microdosing psilocybin for Major Depressive Disorders. I have published many papers on microdosing, including some of the largest samples in the literature and some that have set standards for performing psychedelic research.

Kevin Bourke

Chief Commercial Officer

Kevin Bourke is a dynamic executive and strategic planner whose career spans over two decades of crafting and elevating world-class Jamaican brands and transformational experiences on the global stage. With a keen understanding of culture, identity, and international markets, he has played a pivotal role in shaping some of Jamaica’s most iconic names — including Appleton Estate Rum, Chris Blackwell’s Rum, and Usain Bolt’s Tracks & Records — bringing them from local roots to international acclaim. His leadership and vision have also been instrumental in major cultural movements such as Fiction and the internationally recognized TmrwTday Wellness Festival.

An innovator at heart, Mr. Bourke seamlessly blends brand strategy with deep cultural resonance. His ability to connect with diverse audiences has established these brands not only as commercial successes but as symbolic ambassadors of Jamaican excellence, fortifying the island’s influence in beverage, music, lifestyle, and experiential sectors.

In recent years, Kevin has steered his strategic acumen toward the cutting-edge psilocybin and wellness industry, becoming a co-founder and Chief Marketing and Branding Officer of Rose Hill, Jamaica’s leading cultivator, exporter, and innovator of psilocybin products and experiences. Through ventures like ONE Retreats, he has helped craft safe, guided psychedelic-assisted healing programs that attract participants from around the world seeking deep personal transformation, including military veterans and international wellness seekers.

Kevin’s impact extends beyond business into industry shaping and policy, as he sits on the Jamaica Psilocybin Mushroom Industry Technical Committee (under the Bureau of Standards) — a pivotal body that is formalizing guidelines and regulatory standards for the emerging legal psilocybin sector in Jamaica. His presence on this committee underscores his leadership role in ensuring the industry’s integrity, safety, and sustainable growth.

Highly regarded for his extensive network throughout Jamaica and internationally, Kevin remains passionately committed to advancing ethical, high-integrity product development and customer-centric experiences at every level. His dedication is driven not only by professional achievement but by a deep vision for human well-being, cultural celebration, and the global evolution of plant-based healing.

Jama Pitman

Regulatory Strategy

Jama Pitman is a seasoned biopharmaceutical executive with extensive expertise in global drug development and commercialization. With over two decades of experience, she has contributed to the development of groundbreaking therapies across oncology, rare diseases, and antivirals. As a strategic leader, she has successfully transitioned companies from private to public markets, navigated complex M&A transactions, and driven innovative drug approvals.

Jama has held executive roles in leading organizations, including Deciphera Pharmaceuticals, where she played a pivotal role in scaling operations from a small, privately held biotech company to a global, multi-product company acquired for $2.4 billion. She brings exceptional skills in regulatory affairs, portfolio management, quality assurance, and clinical operations, longside a proven track record of fostering inclusivity and mentorship within her teams.

Currently, as the founder of JP BioPharma Consulting, Jama advises biopharma and tech companies on accelerating drug development and achieving corporate goals. Her collaborative and forward-thinking approach aligns seamlessly with Rose Hill’s mission to advance transformative therapies in mental health and beyond.

Education: B.Sc. in Microbiology, University of New Hampshire.

Notable Achievements: Contributed to the development of multiple FDA-approved therapies, including QINLOCK® for gastrointestinal stromal tumors.

Domenic Suppa

Chief Operating Officer

Domenic is co-founder and the Operations Chief of Rose Hill Health Holdings.

He has been working as a Cannabis technology and operations veteran with more than 11 years’ experience as a senior executive in an operationally complex, and highly regulated industry.

His introduction and entrance into the Cannabis sector started in 2010 with a seed investment into a Denver-based vertically integrated cannabis company called, Evolab. He served as C.O.O. for 5 years from 2013-2018, through the eventual acquisition by Harvest Health and Recreation (HARV: CSE).

Domenic moved on to be acting COO of the manufacturing division for Supreme Cannabis (CSE: FIRE) and supported the acquisition of BLISSCO (CSE: BLISS, a BC-based cannabis manufacturer). Domenic has worked with high-profile national cannabis brands including KKE, and Monogram, and retail brands in MA Native Sun, Terps, and Tilt. Domenic is a proven leader and team builder; his previous experiences have all been with early-stage and growth equity enterprises.

He has refined and evolved his leadership roles, including his team-building skills. He is a value creator. Domenic is a firm believer in training and continuous development. He excels in employing practices, tools, and methodologies designed to achieve maximum process efficiency while minimizing waste and delays.

 

Burton J. Tabaac

Clinical Development

Dr. Burton J. Tabaac, MD, FAHA, brings a wealth of expertise in neurology and stroke rehabilitation to Rose Hill. As an Associate Professor and Section Chief of Neurology at The University of Nevada’s Reno School of Medicine, and Medical Director of Stroke at Carson Tahoe Health, Dr. Tabaac has been at the forefront of innovative neurological treatments.

A graduate of the prestigious cerebrovascular neurology fellowship program at The Johns Hopkins University Hospital, Dr. Tabaac’s accolades include being a three-time recipient of The Arnold P. Gold Foundation’s Humanism and Excellence in Teaching Award and induction into the Alpha Omega Alpha Honor Medical Society.

He recently published an eight-part paper in the American Journal of Therapeutics reviewing psychedelics as therapeutics for primary care clinicians. Dr. Tabaac’s groundbreaking research focuses on the application of psychedelics in brain injury and stroke rehabilitation.

Dr. Tabaac was recently appointed by the Governor of Nevada to serve as a member of the state’s Psychedelic Medicines Working Group, which provides expertise and testimony relating to the therapeutic use of entheogens.

As the host of The Zero Hour Podcast, he engages with leading experts in psychedelic research. His commitment to advancing the field was further highlighted in his 2022 TEDx talk at UCLA, “Mental Health Meets Psychedelics.”

“Joining Rose Hill’s advisory team presents an exciting opportunity to further explore the potential of psilocybin in neurological recovery,” said Dr. Tabaac.

“The company’s commitment to ethical cultivation and research aligns perfectly with my vision for advancing patient care through innovative therapies. I’m eager to bring my expertise to Rose Hill and contribute to the evolving landscape of psychedelic medicine.”

Charles Lazarus

Chief Executive Office

Mr. Lazarus boasts over 16 years of extensive expertise in psilocybin and cannabis, focusing on genetic development, cultivation, extraction, and operations logistics. Notably, he recently achieved a milestone by cultivating and delivering the largest legal shipment of premium psilocybin globally.

As an accomplished owner/operator, Mr. Lazarus has successfully managed multiple farming and harvesting businesses, earning commendations for his unwavering commitment to quality and impressive output volumes. Since 2015, he has been actively involved in producing proprietary psilocybin genetics and cultivation solutions tailored for the Jamaican market and large research and development clients.

His contributions span various aspects, including genetic development, cultivation, extraction, harvest, and logistics. Additionally, Mr. Lazarus owned and operated Island Fresh Ltd., a venture that played a pivotal role in exporting fresh fruit, ground provisions, and promoting brand Jamaica to the English market. Under his leadership, Island Fresh Ltd. achieved the highest volume from Jamaica for three consecutive years.

Mr. Lazarus’s extensive experience also includes serving as the Harvest Manager for cannabis grow operations in California from 2013 to 2017, further solidifying his comprehensive knowledge in the cannabis industry.